324 filings
Page 4 of 17
8-K
b0irpq0b 0olr878jmn
10 May 21
PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint
8:00am
8-K
7727lv8mv61b6sw
19 Apr 21
Departure of Directors or Certain Officers
4:30pm
8-K
2j12r
30 Mar 21
PolarityTE Reports Fourth Quarter and Fiscal Year 2020 Results
7:00am
8-K
77cqfyiuby l6
9 Mar 21
Regulation FD Disclosure
7:00am
8-K
0tnp3wemohoa xk9
10 Feb 21
PolarityTE Provides Corporate Update
8:00am
8-K
yz7afc17phwl4u 27j19
3 Feb 21
PolarityTE Receives Allowance for Additional U.S. Patent
5:25pm
8-K
b0v4y
27 Jan 21
Other Events
8:00am
8-K
5jzohsdvpmokn 6q7
26 Jan 21
Entry into a Material Definitive Agreement
4:30pm
8-K
sm1p7mdofnddyf3
22 Jan 21
PolarityTE, Inc. Announces Exercise of Warrants for Gross Proceeds of $7.67 Million
8:55am
8-K
1igtmo
21 Jan 21
PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial
8:00am
8-K
w0kkpc4wlvcfraxc
14 Jan 21
PolarityTE Announces Closing of $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:15pm
8-K
m0wwmet id6aky4j0w
12 Jan 21
PolarityTE Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
7:15am
8-K
ng540i8i
11 Jan 21
PolarityTE Announces Formation of Strategic Review Committee
8:15am
8-K
uutk5h3vq98uf wts0
23 Dec 20
Entry into a Material Definitive Agreement
4:05pm
8-K
3mb 1e5haua
22 Dec 20
PolarityTE Announces $8.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
8:15am
8-K
4rfsrtgry vmaagxd5c
11 Dec 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
9pbcit 5uh
30 Nov 20
PolarityTE Receives Allowance for First U.S. Patent
8:00am
8-K
6m1h36vft
23 Nov 20
Submission of Matters to a Vote of Security Holders
8:05am
8-K
vp0ji 0yh
9 Nov 20
PolarityTE Reports Third Quarter 2020 Results
7:00am
8-K
x6cxyko fjtqmij89n
2 Nov 20
PolarityTE Announces Successful Completion of Initial
8:01am